12/15/2022 – 9:54 AM EST – IMV Inc. : Introduced optimistic preliminary affected person knowledge from the VITALIZE Part 2B trial evaluating its lead DPX product, MVP-S, together with pembrolizumab in sufferers with relapsed, refractory Diffuse Giant B Cell Lymphoma (“r/r DLBCL”) who acquired at the very least three earlier traces of remedy. Detailed outcomes will likely be offered in a podium presentation on the Immuno-Oncology 360° convention to be held in New York Metropolis on February 7-10, 2023. IMV Inc.
shares T.IMV are buying and selling up $0.70 at $3.65.
Supply hyperlink
